In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection
In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection
复制标题
DOI:
10.1016/j.arcmed.2014.12.002
复制
发表时间:
2015-01-01
影响因子:
7.7
通讯作者:
Kobayashi, Nobuyuki
中科院分区:
文献类型:
--
作者:
Charyasriwong, Siriwan;Watanabe, Ken;Kobayashi, Nobuyuki
Background and Aims. Influenza virus infections are serious public health concerns worldwide that cause considerable mortality and morbidity. Moreover, the emergence of resistance to anti-influenza viral agents underscores the need to develop new anti-influenza viral agents and novel treatment strategies. Recently, we identified anti-influenza viral activity of manuka honey. Therefore, we hypothesized that methylglyoxal (MGO), a key component of manuka honey, may impart anti-influenza viral activity. The aim of this study was to evaluate the anti-influenza viral activity of MGO and its potential in combination treatments with neuraminidase (NA) inhibitors.Methods. MDCK cells were used to evaluate anti-influenza viral activity. To evaluate the mechanism of MOO, plaque inhibition assays were performed. The synergistic effects of MOO and viral NA inhibitors were tested.Results. MGO inhibited influenza virus A/WSN/33 replication 50% inhibitory concentration = 240 +/- 190 mu M; 50% cytotoxic concentration = 1.4 +/- 0.4 mM; selective index (SI) = 5.8, which is related to its virucidal effects. Moreover, we found that MOO showed promising activity against various influenza strains. A synergistic effect was observed by a marked increase in SI of NA inhibitors at similar to 1/100th of their single usage. A synergistic effect of MOO and oseltamivir was also observed against oseltamivir-resistant virus.Conclusions. Our results showed that MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors. Thus, the co-administration of MGO and NA inhibitors should be considered for treatment of influenza virus infections. (C) 2015 IMSS. Published by Elsevier Inc.